Skip to main content

Table 1 Baseline characteristics for the overall population and for controls and cases with AT level below 70%

From: Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study

Characteristic

Overall population (n = 106)

Period 1 (2001–2002) (n = 40)

Period 2 (2003–2004) (n = 38)

p d

Age, years

59.6 ± 14.5

58.4 ± 14.5

60.5 ± 13.4

0.50

Male sex, n

70 (66)

27 (68)

27 (71)

0.81

Medical admission, n

85 (80)

33 (82)

30 (79)

0.78

Coexisting conditions, n

    

   Chronic liver disease

16 (15)

6 (15)

7 (18)

0.77

   Immune deficiency

20 (19)

8 (20)

7 (18)

1.0

   Chronic renal failure

9 (8)

2 (5)

4 (11)

0.42

Site of infection, n

   

0.93

   Respiratory system

61 (58)

22 (55)

22 (58)

 

   Intra-abdominal

19 (18)

9 (22)

7 (18)

 

   Urinary system

15 (14)

4 (10)

3 (8)

 

   Other

11 (10)

5 (13)

6 (16)

 

Microbial type, n

   

0.89

   Gram-negative

22 (21)

9 (22)

9 (24)

 

   Gram-positive

32 (30)

10 (25)

12 (32)

 

   Other/mixed

15 (14)

3 (8)

3 (8)

 

   Unknown

37 (35)

18 (45)

14 (36)

 

SAPS II

58.2 ± 16.3

55.2 ± 16.0

62.5 ± 16.1

0.047

SOFA score

8 (3–21)

8 (3–20)

10 (3–21)

0.012

Overt DIC, n

20 (19)

7 (18)

8 (21)

0.78

Need for mechanical ventilation, n

82 (77)

30 (75)

30 (79)

0.79

Length of vasoactive support, days

6 (1–15)

6 (1–15)

6.5 (1–14)

0.79

Time between ICU admission and onset of CRRT, days

1 (0–7)

1 (0–7)

1 (0–7)

0.86

Serum creatininea, μmol/l

158 (82–480)

126 (94–380)

158 (82–480)

0.47

Blood urea nitrogena, mmol/l

16.2 (5.5–57)

15.9 (8.8–50.6)

17.6 (6.2–57)

0.20

Fibrinogena, g/l

6.2 ± 1.4

6.5 ± 1.3

6.5 ± 1.4

0.86

Plateletsa, 103/μl

114 (8–654)

107 (8–570)

92 (11–654)

0.80

Antithrombin activity levela, %

62.5 ± 19.1

53.5 ± 10.4

51.9 ± 11.2

0.53

Femoral angioaccess, n

66 (62)

25 (62)

21 (55)

0.65

APTT ratiob

2.2 ± 0.7

1.9 ± 0.5

2.0 ± 0.6

0.80

Heparin doseb, U/kg

771 ± 333

890 ± 389

683 ± 276

0.0086

Filter clotting rate, %

22

31.8 ± 25.0

16.5 ± 15.2

0.0018

Ultrafiltration rate, ml/kg per hour

34.1 ± 3.6

33.2 ± 3.4

34.4 ± 3.7

0.14

Ratio of delivered to prescribed ultrafiltration, %

83.1 ± 12.7

77.3 ± 12.3

86.1 ± 13.2

0.0032

Length of CRRT, days

4 (1–9)

4 (1–8)

4 (1–8)

0.85

Length of stay in ICU, days

10 (2–105)

8 (2–49)

11 (2–92)

0.22

Expected mortality, %

59.1 ± 24.1

54.0 ± 25.5

61.1 ± 23.8

0.21

   ICU mortality, n

64 (60)

26 (65)

22 (58)

0.64

   Hospital mortality, n

66 (62)

27 (68)

23 (60)

0.64

   O/E ratio

1.1 [0.9–1.4]

1.4 [1.1–1.8]c

1.1 [0.9–1.4]

 
  1. aWhen initiating CRRT; bmeans of APTT ratio and heparin dose during CRRT; c95% confidence interval significantly different from 1; dp value for univariate analysis between periods 1 and 2. Single numbers in parentheses are percentages; ranges are shown in parentheses; square brackets are used to indicate 95% confidence interval. APTT, activated partial thromboplastin time; CRRT, continuous renal replacement therapy; DIC, disseminated intravascular coagulopathy; O/E ratio, risk-adjusted mortality rate; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.